The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

Shiraki, Aya; Oyama, Jun‐ichi; Komoda, Hiroshi; Asaka, Machiko; Komatsu, Aiko; Sakuma, Masashi; Kodama, Kazuhisa; Sakamoto, Yoshiko; Kotooka, Norihiko; Hirase, Tetsuaki; Node, Koichi

doi:10.1016/j.atherosclerosis.2011.12.039

Cited by 230 publications

(152 citation statements)

References 28 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…Experimental studies have demonstrated that GLP‐1 agonists have anti‐inflammatory effects on endothelial cells. Treatment with the GLP‐1 receptor agonist liraglutide inhibited tumor necrosis factor‐α, intracellular adhesion molecule‐1 and vascular cell adhesion molecule‐1 in human endothelial cells 66, 67. In animal models, liraglutide has been shown to reduce serum levels of several inflammatory markers such us C‐reactive protein, interleukin‐6, tumor necrosis factor‐α and the plasmin plasminogen activator inhibitor‐1 68…”

Section: Discussionmentioning

confidence: 99%

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus

Bretón‐Romero

Weisbrod

Feng

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundPrior studies have shown that nutrient excess induces endoplasmic reticulum (ER) stress in nonvascular tissues from patients with diabetes mellitus (DM). ER stress and the subsequent unfolded protein response may be protective, but sustained activation may drive vascular injury. Whether ER stress contributes to endothelial dysfunction in patients with DM remains unknown.Methods and ResultsTo characterize vascular ER stress, we isolated endothelial cells from 42 patients with DM and 37 subjects without DM. Endothelial cells from patients with DM displayed higher levels of ER stress markers compared with controls without DM. Both the early adaptive response, evidenced by higher phosphorylated protein kinase–like ER eukaryotic initiation factor‐2a kinase and inositol‐requiring ER‐to‐nucleus signaling protein 1 (P=0.02, P=0.007, respectively), and the chronic ER stress response evidenced by higher C/EBPα‐homologous protein (P=0.02), were activated in patients with DM. Higher inositol‐requiring ER‐to‐nucleus signaling protein 1 activation was associated with lower flow–mediated dilation, consistent with endothelial dysfunction (r=0.53, P=0.02). Acute treatment with liraglutide, a glucagon‐like peptide 1 receptor agonist, reduced p‐inositol‐requiring ER‐to‐nucleus signaling protein 1 (P=0.01), and the activation of its downstream target c‐jun N‐terminal kinase (P=0.025) in endothelial cells from patients with DM. Furthermore, liraglutide restored insulin‐stimulated endothelial nitric oxide synthase activation in patients with DM (P=0.019).ConclusionsIn summary, our data suggest that ER stress contributes to vascular insulin resistance and endothelial dysfunction in patients with DM. Further, we have demonstrated that liraglutide ameliorates ER stress, decreases c‐jun N‐terminal kinase activation and restores insulin‐mediated endothelial nitric oxide synthase activation in endothelial cells from patients with DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus

Bretón‐Romero

Weisbrod

Feng

et al. 2018

JAHA

View full text Add to dashboard Cite

show abstract

“…Mice were given 10 µg/kg exendin-4, and after 48 wk of treatment, results showed that activation of NF-κB was reduced; exendin-4 also significantly inhibited the binding activity of NFκBp65 in patients with diabetes mellitus [45] . Liraglutide significantly inhibited NF-κB activation and up-regulated the IκB family of proteins while phosphorylation of IKK-α/β, which is upstream of NF-κB signaling, was also down-regulated after 15 min of TNF-α treatment [73] . ERK 1/2 and PI3-K/AKT are involved in LPS-induced NF-κB activation [74,75] .…”

Section: Glp-1ras and Inflammatory Signal Transduction Pathwaysmentioning

confidence: 94%

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Wang¹

2014

WJG

View full text Add to dashboard Cite

Glucagon-like peptide1 (GLP-1) is secreted from Langerhans cells in response to oral nutrient intake. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new class of incretin-based anti-diabetic drugs. They function to stimulate insulin secretion while suppressing glucagon secretion. GLP-1-based therapies are now well established in the management of type 2 diabetes mellitus (T2DM), and recent literature has suggested potential applications of these drugs in the treatment of obesity and for protection against cardiovascular and neurological diseases. As we know, along with change in lifestyles, the prevalence of non-alcoholic fatty liver disease (NAFLD) in China is rising more than that of viral hepatitis and alcoholic fatty liver disease, and NAFLD has become the most common chronic liver disease in recent years. Recent studies further suggest that GLP1RAs can reduce transaminase levels to improve NAFLD by improving blood lipid levels, cutting down the fat REVIEW 14821October 28, 2014|Volume 20|Issue 40| WJG|www.wjgnet.com content to promote fat redistribution, directly decreasing fatty degeneration of the liver, reducing the degree of liver fibrosis and improving inflammation. This review shows the NAFLD-associated effects of GLP-1RAs in animal models and in patients with T2DM or obesity who are participants in clinical trials.

show abstract

“…Furthermore, recent studies have shown that GLP-1 reduces inflammation and oxidative stress in endothelial cells (11,12). The importance of GLP-1 in glucose homeostasis is emphasized by the inhibitors of dipeptidyl peptidase-4 (DPP-4); enzymes which have been found to exert positive effects on cardioprotection in previous studies (13,14).…”

Section: Introductionmentioning

confidence: 99%

Sitagliptin attenuates inﬂammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition

Lin¹,

Lin²

2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Glucagon-like peptide-1 (GLP-1) and GLP-1 receptors (GLP-1Rs) are responsible for glucose homeostasis, and have been shown to reduce inflammation in preclinical studies. The aim of the present study was to determine whether sitagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), as a GLP-1 receptor agonist, exerts an anti-inflammatory effect on cardiomyoblasts during lipopolysaccharide (LPS) stimulation. Exposure to LPS increased the expression levels of tumor necrosis factor (TNF)-α, interleukin-6 (IL)-6 and IL-1β in H9c2 cells, and also resulted in elevations in cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) expression and nuclear factor-κB (NF-κB) nuclear translocation. Treatment with the DPP-4 inhibitor sitagliptin dose-dependently downregulated the mRNA levels of IL-6, COX-2 and iNOS in LPS-stimulated H9c2 cells. In addition, sitagliptin inhibited the increased protein expression of IL-6, TNF-α and IL-1β. NF-κB mRNA expression was reduced and its translocation to the nucleus was suppressed by treatment with sitagliptin. The present results demonstrated that sitagliptin exerts a beneficial effect on cardiomyoblasts exposed to LPS by inhibiting expression of inflammatory mediators and suppressing NF-κB activation. These findings indicate that the DPP-4 inhibitor sitagliptin may serve a function in cardiac remodeling attributed to sepsis-induced inflammation.

show abstract

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

Cited by 230 publications

References 28 publications

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus

Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation

Sitagliptin attenuates inﬂammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition

Contact Info

Product

Resources

About